Biological therapy of psoriasis

Raja K Sivamani, Genevieve Correa, Yoko Ono, Michael P. Bowen, Siba P Raychaudhuri, Emanual Michael Maverakis

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. These medications are designed to target specific components of the immune system and are a major technological advancement over traditional immunosuppressive medications. These usually being well tolerated are being found useful in a growing number of immune-mediated diseases, psoriasis being just one example. The newest biologic, ustekinumab, is directed against the p40 subunit of the IL-12 and IL-23 cytokines. It has provided a new avenue of therapy for an array of T-cell-mediated diseases. Biologics are generally safe; however, there has been concern over the risk of lymphoma with use of these agents. All anti-TNF- agents have been associated with a variety of serious and "routine" opportunistic infections.

Original languageEnglish (US)
Pages (from-to)161-170
Number of pages10
JournalIndian Journal of Dermatology
Issue number2
StatePublished - Apr 1 2010


  • Adverse effects
  • Biologics
  • Psoriasis
  • Therapy

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Biological therapy of psoriasis'. Together they form a unique fingerprint.

Cite this